The Potential of Saffron as an Add-on in Treating Mild to Moderate Depression in Adults: A Literature Review
DOI:
https://doi.org/10.61173/jxsrvv02Keywords:
-saffron, depression, herbal, antidepressant, adjunctive therapyAbstract
Depression is one of the most prevalent mental health disorders affecting five percent of the world’s adults. Depression can cause suicide which is one of the top four causes of death for people aged 15-29 (World Health Organization, 2023). Due to its prevalence in the global population, the treatment of depression has received much attention. Despite advancements in treatment, current approaches often yield suboptimal results, with many medications associated with significant side effects. This has led to a global trend toward exploring natural therapies with stronger efficiency and fewer adverse effects. Saffron is a medicinal herbal and its extracts have emerged as a promising candidate due to its demonstrated antidepressant properties, especially in the treatment of mild to moderate depression. However, the application of saffron as a therapeutic option is complicated by its high cost, which led to issues with product authenticity (Raina et al., 2023), and concerns regarding long-term safety and tolerability. This literature review aims to provide a comprehensive analysis of saffron’s potential as a treatment for depression by critically examining the advantages and limitations of using saffron in this context, including its efficacy, safety profile, and economic viability. It will also summarize the interesting findings from former clinical trials. In short, the review seeks to assess the feasibility of incorporating saffron as an adjunctive therapy for mild to moderate depression in adults, highlighting both its potential benefits and the challenges that need to be addressed for broader clinical use.
References
Amin, F. (2023). Co-administration of saffron and chamomile: To determine the efficacy as an adjuvant therapy for mild to moderate depression in human subjects. A pilot randomized clinical trial. JPMA. The Journal of the Pakistan Medical Association, 73(6), 1245–1250. https://doi.org/10.47391/ JPMA.3915 Akhondzadeh, S., Mostafavi, S.-A., Keshavarz, S. A.,
Mohammadi, M. R., Hosseini, S., & Eshraghian, M. R. (2020). A placebo controlled randomized clinical trial of crocus sativus L. (saffron) on depression and food craving among overweight women with mild to moderate depression. Journal of Clinical Pharmacy and Therapeutics, 45(1), 134–143. https://doi. org/10.1111/jcpt.13040 Bertagna , B. (2023, December 29). Saffron for depression: How this beautiful spice can help manage low mood. Rupa Health. https://www.rupahealth.com/post/saffron-for-depression-howthis-beautiful-spice-can-help-manage-low-mood Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., &
Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi. org/10.1016/s0140-6736(17)32802-7 Clement, K., Covertson, C. R., Johnson, M. J., & Dearing, K. (2006). St. johnʼs wort and the treatment of mild to moderate depression. Holistic Nursing Practice, 20(4), 197–203. https:// doi.org/10.1097/00004650-200607000-00008
Cleveland Clinic. (2023). Depression symptoms, causes, & treatment . Cleveland Clinic. https://my.clevelandclinic.org/ health/diseases/9290-depression
Dai, L., Chen, L., & Wang, W. (2020). Safety and efficacy of saffron (crocus sativus L.) for treating mild to moderate depression. The Journal of Nervous and Mental Disease, 208(4), 269–276. https://doi.org/10.1097/nmd.0000000000001118 Darbinyan, V., Aslanyan, G., Amroyan, E., Gabrielyan, E.,
Malmström, C., & Panossian, A. (2007). Clinical trial of rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic Journal of Psychiatry, 61(5), 343– 348. https://doi.org/10.1080/08039480701643290
Gotlib, I. H., & Joormann, J. (2010). Cognition and depression: Current status and future directions. Annual Review of Clinical Psychology, 6(1), 285–312. https://doi.org/10.1146/annurev. clinpsy.121208.131305
Gracia, L., Perez-Vidal, C., & Gracia-López, C. (2009). Automated cutting system to obtain the stigmas of the saffron flower. Biosystems Engineering, 104(1), 8–17. https://doi. org/10.1016/j.biosystemseng.2009.06.003 Harvard Health Publishing. (2019, March 13). Persistent depressive disorder (dysthymia) - harvard health. Harvard Health; Harvard Health. https://www.health.harvard.edu/a_to_ z/dysthymia-a-to-z Dean&Francis Jiayi Sun Jakubovski, E., Varigonda, A. L., Freemantle, N., Taylor, M. J., & Bloch, M. H. (2016). Systematic review and meta-analysis: Dose-Response relationship of selective serotonin reuptake inhibitors in major depressive disorder. American Journal of Psychiatry, 173(2), 174–183. https://doi.org/10.1176/appi. ajp.2015.15030331
Jelodar, G., Javid, Z., Sahraian, A., & Jelodar, S. (2018). Saffron improved depression and reduced homocysteine level in patients with major depression: A randomized, double-blind study. Avicenna Journal of Phytomedicine, 8(1), 43–50. https://www. ncbi.nlm.nih.gov/pmc/articles/PMC5787996/ Jéssica Serrano-Díaz, Sánchez, A. M., Martínez‐Tomé,
M., Winterhalter, P., & Alonso, G. L. (2014). Flavonoid determination in the quality control of floral bioresidues from crocus sativus L.. Journal of Agricultural and Food Chemistry, 62(14), 3125–3133. https://doi.org/10.1021/jf4057023 Keefe, J. R., Mao, J. J., Soeller, I., Li, Q. S., & Amsterdam,
J. D. (2016). Short-term open-label chamomile (matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder. Phytomedicine, 23(14), 1699–1705. https://doi. org/10.1016/j.phymed.2016.10.013
Khalil, S. A. (2022). Saffron as a treatment for mild to moderate depression: A revision of current literature. Journal of European Psychology Students, 13(1), 1–6. https://doi.org/10.5334/ jeps.529
Kumari, L., Jaiswal, P., & Tripathy, S. S. (2021). Various techniques useful for determination of adulterants in valuable saffron: A review. Trends in Food Science & Technology, 111, 301–321. https://doi.org/10.1016/j.tifs.2021.02.061 Li, X., Xie, J., Hong Jin Fan, Tan, J., Zhang, D., Yang, B.,
Geng, F., Pei, J., & Ma, H. (2023). Stigma and petals of Crocus sativus L.: Review and comparison of phytochemistry and pharmacology. Arabian Journal of Chemistry, 16(8), 104918– 104918. https://doi.org/10.1016/j.arabjc.2023.104918
Lopresti, A. L., & Drummond, P. D. (2017). Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. Journal of Affective Disorders, 207, 188–196. https://doi. org/10.1016/j.jad.2016.09.047 Lopresti, A. L., Smith, S. J., Hood, S. D., & Drummond, P. D. (2019). Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, doubleblind, placebo-controlled study. Journal of Psychopharmacology, 33(11), 1415–1427. https://doi.org/10.1177/0269881119867703 Marrone, G., Urciuoli, S., Manuela Di Lauro, Cornali, K., Montalto, G., Masci, C., Vanni, G., Tesauro, M., Vignolini, P., &
Noce, A. (2024). Saffron (Crocus sativus L.) and Its By-Products: Healthy Effects in Internal Medicine. Nutrients, 16(14), 2319– 2319. https://doi.org/10.3390/nu16142319
Plante, G. E. (2005). Depression and cardiovascular disease: a reciprocal relationship. Metabolism, 54(5), 45–48. https://doi. org/10.1016/j.metabol.2005.01.013
Raina, A., Kaul, S., & Dhar, M. K. (2023). Sniffing out adulteration in saffron-detection methods and health risks. Food Control, 110042–110042. https://doi.org/10.1016/ j.foodcont.2023.110042 Raman, R. (2023, February 1). 11 impressive health benefits of saffron. Healthline. https://www.healthline.com/nutrition/saffron
Razavi, B. M., & Hosseinzadeh, H. (2017). Saffron: a promising natural medicine in the treatment of metabolic syndrome. Journal of the Science of Food and Agriculture, 97(6), 1679– 1685. https://doi.org/10.1002/jsfa.8134 Rengasamy, K. R. R., Khan, H., Gowrishankar, S., Lagoa, R. J. L., Mahomoodally, F. M., Khan, Z., Suroowan, S., Tewari, D.,
Zengin, G., Hassan, S. T. S., & Pandian, S. K. (2019). The role of flavonoids in autoimmune diseases: Therapeutic updates. Pharmacology & Therapeutics, 194, 107–131. https://doi. org/10.1016/j.pharmthera.2018.09.009
Schildkraut, J. J. (1995). The catecholamine hypothesis of affective disorders: A review of supporting evidence. 1965 [classical article]. The Journal of Neuropsychiatry and Clinical Neurosciences, 7(4), 524–533. https://doi.org/10.1176/ jnp.7.4.524
Seyedeh Farzaneh Omidkhoda, & Hosseinzadeh, H. (2022). Saffron and its active ingredients against human disorders: A literature review on existing clinical evidence. PubMed, 25(8), 913–933. https://doi.org/10.22038/ijbms.2022.63378.13985 Tabeshpour, J., Sobhani, F., Sadjadi, S. A., Hosseinzadeh, H.,
Mohajeri, S. A., Rajabi, O., Taherzadeh, Z., & Eslami, S. (2017). A double-blind, randomized, placebo-controlled trial of saffron stigma (Crocus sativus L.) in mothers suffering from mild-tomoderate postpartum depression. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 36, 145–152. https://doi.org/10.1016/j.phymed.2017.10.005 Talaei, A., Hassanpour Moghadam, M., Sajadi Tabassi, S.
A., & Mohajeri, S. A. (2015). Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial. Journal of Affective Disorders, 174, 51–56. https:// doi.org/10.1016/j.jad.2014.11.035 Tóth, B., Hegyi, P., Lantos, T., Szakács, Z., Kerémi, B., Varga, G., Tenk, J., Pétervári, E., Balaskó, M., Rumbus, Z., Rakonczay,
Z., Bálint, E. R., Kiss, T., & Csupor, D. (2019). The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. Planta Medica, 85(1), 24–31. https://doi. org/10.1055/a-0660-9565 Vignolini, P., Heimler, D., Pinelli, P., Ieri, F., Sciullo, A., & Romani, A. (2008). Characterization of by-products of saffron (crocus sativus L.) production. Natural Product Communications, 3(12), 1934578X0800301. https://doi. org/10.1177/1934578x0800301203 World Health Organization. (2023, March 31). Depressive disorder (depression). World Health Organization. https://www. who.int/news-room/fact-sheets/detail/depression
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
